PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 151 filers reported holding PROGENICS PHARMACEUTICALS IN in Q1 2019. The put-call ratio across all filers is 1.60 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $402,000 | -82.8% | 105,821 | -77.0% | 0.00% | -100.0% |
| Q4 2019 | $2,336,000 | +97.0% | 459,214 | +95.6% | 0.00% | 0.0% |
| Q3 2019 | $1,186,000 | -23.8% | 234,749 | -7.0% | 0.00% | 0.0% |
| Q2 2019 | $1,557,000 | +135.9% | 252,401 | +77.5% | 0.00% | – |
| Q1 2019 | $660,000 | -1.3% | 142,228 | -10.8% | 0.00% | – |
| Q4 2018 | $669,000 | -61.8% | 159,492 | -42.9% | 0.00% | -100.0% |
| Q3 2018 | $1,753,000 | -21.3% | 279,435 | +0.8% | 0.00% | -50.0% |
| Q2 2018 | $2,227,000 | +49.3% | 277,106 | +38.6% | 0.00% | +100.0% |
| Q1 2018 | $1,492,000 | +56.9% | 199,964 | +25.1% | 0.00% | – |
| Q4 2017 | $951,000 | -23.1% | 159,786 | -4.8% | 0.00% | -100.0% |
| Q3 2017 | $1,236,000 | +23.4% | 167,800 | +13.5% | 0.00% | +100.0% |
| Q2 2017 | $1,002,000 | +7.5% | 147,778 | +49.6% | 0.00% | 0.0% |
| Q1 2017 | $932,000 | +78.5% | 98,760 | +63.4% | 0.00% | – |
| Q4 2016 | $522,000 | +82.5% | 60,455 | +34.1% | 0.00% | – |
| Q3 2016 | $286,000 | +2500.0% | 45,089 | +1570.0% | 0.00% | – |
| Q2 2016 | $11,000 | -78.4% | 2,700 | -78.6% | 0.00% | – |
| Q1 2016 | $51,000 | +64.5% | 12,592 | +134.5% | 0.00% | – |
| Q4 2015 | $31,000 | -71.6% | 5,369 | -75.5% | 0.00% | – |
| Q3 2015 | $109,000 | -91.1% | 21,886 | -87.5% | 0.00% | -100.0% |
| Q2 2015 | $1,223,000 | +42.9% | 174,869 | +2.2% | 0.00% | – |
| Q1 2015 | $856,000 | +215.9% | 171,081 | +342.7% | 0.00% | – |
| Q4 2014 | $271,000 | +129.7% | 38,649 | +64.4% | 0.00% | – |
| Q3 2014 | $118,000 | -23.4% | 23,512 | -38.9% | 0.00% | – |
| Q2 2014 | $154,000 | -45.8% | 38,465 | -45.5% | 0.00% | – |
| Q1 2014 | $284,000 | -11.0% | 70,514 | +10.8% | 0.00% | – |
| Q4 2013 | $319,000 | +50.5% | 63,625 | +50.6% | 0.00% | – |
| Q3 2013 | $212,000 | -40.4% | 42,245 | -47.0% | 0.00% | – |
| Q2 2013 | $356,000 | – | 79,719 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARDSLEY ADVISORY PARTNERS LP | 1,255,000 | $5,823,000 | 1.12% |
| Phocas Financial Corp. | 1,146,292 | $5,319,000 | 0.54% |
| Worth Venture Partners, LLC | 138,357 | $641,000 | 0.36% |
| RICE HALL JAMES & ASSOCIATES, LLC | 2,293,179 | $10,640,000 | 0.34% |
| Monashee Investment Management LLC | 240,000 | $1,114,000 | 0.26% |
| BKS ADVISORS, LLC | 118,587 | $550,000 | 0.22% |
| PINNACLE ASSOCIATES LTD | 1,418,391 | $6,581,000 | 0.15% |
| FARALLON CAPITAL MANAGEMENT LLC | 4,200,820 | $19,492,000 | 0.15% |
| Fosun International Ltd | 472,580 | $2,174,000 | 0.14% |
| CARILLON TOWER ADVISERS, INC. | 3,948,024 | $18,318,000 | 0.13% |